| HVAD: The ENDURANCE Supplemental Trial |
39 |
| Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure |
39 |
| The Association of Obesity and Cardiometabolic Traits With Incident HFpEF and HFrEF |
37 |
| Iron Deficiency in Heart Failure An Overview |
35 |
| Hypertrophic Cardiomyopathy |
35 |
| Venoarterial Extracorporeal Membrane Oxygenation in Cardiogenic Shock |
35 |
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of the Oral Soluble Guanylate Cyclase Stimulator The VICTORIA Trial |
32 |
| Contemporary Drug Treatment of Chronic Heart Failure With Reduced Ejection Fraction The CHECK-HF Registry |
32 |
| Effects of Vildagliptin on Ventricular Function in Patients With Type 2 Diabetes Mellitus and Heart Failure |
31 |
| Integrative Assessment of Congestion in Heart Failure Throughout the Patient Journey |
29 |
| Cardiogenic Shock in Takotsubo Cardiomyopathy Versus Acute Myocardial Infarction An 8-Year National Perspective on Clinical Characteristics, Management, and Outcomes |
29 |
| Heart Failure With Preserved Ejection Fraction Expert Panel Report Current Controversies and Implications for Clinical Trials |
27 |
| Screening for Transthyretin Amyloid Cardiomyopathy in Everyday Practice |
27 |
| Temporal Trends in the Incidence of and Mortality Associated With Heart Failure With Preserved and Reduced Ejection Fraction |
26 |
| Indications for Cardiac Resynchronization Therapy A Comparison of the Major International Guidelines |
26 |
| Post-Myocardial Infarction Heart Failure |
25 |
| The REDUCE FMR Trial A Randomized Sham-Controlled Study of Percutaneous Mitral Annuloplasty in Functional Mitral Regurgitation |
25 |
| Prevalence and Prognostic Significance of Malnutrition Using 3 Scoring Systems Among Outpatients With Heart Failure |
24 |
| Obesity-Related Heart Failure With a Preserved Ejection Fraction The Mechanistic Rationale for Combining Inhibitors of Aldosterone, Neprilysin, and Sodium-Glucose Cotransporter-2 |
24 |
| Hemodynamic Correlates and Diagnostic Role of Cardiopulmonary Exercise Testing in Heart Failure With Preserved Ejection Fraction |
22 |
| Outcomes and Effect of Treatment According to Etiology in HFrEF An Analysis of PARADIGM-HF |
22 |
| Forgotten No More A Focused Update on the Right Ventricle in Cardiovascular Disease |
21 |
| Aortic Insufficiency During Contemporary Left Ventricular Assist Device Support Analysis of the INTERMACS Registry |
21 |
| Unloading of the Left Ventricle During Venoarterial Extracorporeal Membrane Oxygenation Therapy in Cardiogenic Shock |
21 |
| Identification of Frailty in Chronic Heart Failure |
21 |
| Performance of Prognostic Risk Scores in Chronic Heart Failure Patients Enrolled in the European Society of Cardiology Heart Failure Long-Term Registry |
21 |
| Regional Adipose Distribution and its Relationship to Exercise Intolerance in Older Obese Patients Who Have Heart Failure With Preserved Ejection Fraction |
20 |
| Initiation, Continuation, Switching, and Withdrawal of Heart Failure Medical Therapies During Hospitalization |
19 |
| Short- and Long-Term Prognostic Relevance of Cardiogenic Shock in Takotsubo Syndrome Results From the RETAKO Registry |
19 |
| A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Cardiac Contractility Modulation |
19 |
| Lung Ultrasound in Acute Heart Failure Prevalence of Pulmonary Congestion and Short- and Long-Term Outcomes |
19 |
| Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction The PARAGON-HF Trial |
18 |
| Long-Term Prognosis and Outcome Predictors in Takotsubo Syndrome A Systematic Review and Meta-Regression Study |
18 |
| Income Inequality and Outcomes in Heart Failure A Global Between-Country Analysis |
18 |
| The Role of the Clinical Examination in Patients With Heart Failure |
18 |
| Cardiac Dysfunction Among People Living With HIV A Systematic Review and Meta-Analysis |
17 |
| Sex-Based Differences in Heart Failure Across the Ejection Fraction Spectrum Phenotyping, and Prognostic and Therapeutic Implications |
17 |
| Physical Activity, Fitness, and Obesity in Heart Failure With Preserved Ejection Fraction |
17 |
| Sex Differences in Outcomes and Responses to Spironolactone in Heart Failure With Preserved Ejection Fraction A Secondary Analysis of TOPCAT Trial |
17 |
| Adiposity and Incident Heart Failure and its Subtypes MESA (Multi-Ethnic Study of Atherosclerosis) |
16 |
| Target Doses of Heart Failure Medical Therapy and Blood Pressure Insights From the CHAMP-HF Registry |
16 |
| Clinical Spectrum and Management of Heart Failure in Hypertrophic Cardiomyopathy |
16 |
| Exercise-Based Rehabilitation for Heart Failure Cochrane Systematic Review, Meta-Analysis, and Trial Sequential Analysis |
15 |
| Sex Differences in Heart Failure With Preserved Ejection Fraction Pathophysiology A Detailed Invasive Hemodynamic and Echocardiographic Analysis |
15 |
| The Future of Wearables in Heart Failure Patients |
15 |
| Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction The TOPCAT Trial |
14 |
| Hemodynamic Effects of Weight Loss in Obesity A Systematic Review and Meta-Analysis |
14 |
| Prevalence and Prognostic Implications of Longitudinal Ejection Fraction Change in Heart Failure |
14 |
| Heart Failure and Liver Disease Cardiohepatic Interactions |
14 |
| Effect of Influenza on Outcomes in Patients With Heart Failure |
14 |
